It is a project that delves into personalized medicine. This trial has been financed by the Carlos III Health Institute through R&D projects call in 2019, and by a grant from the Spanish Society of Cardiology.
The study compares the use of two drugs through what they have called a natural experiment, which opens the doors to a new research methodology to compare highly effective treatments, minimizing possible biases in the analysis of the different groups.
This course, the educational project has been implemented in a group of Baccalaureate from the Escola Pia of Igualada
This is the largest and most complete study carried out on the subject, it has included more than 450,000 people from 9 European countries and has analyzed the relationship of diet with 25 different types of cancer. The work concludes that replacing 10% of the intake of processed products with others that are not reduces the risk of suffering any type of cancer.
Between 2018 and 2019, the IDIBELL and Bellvitge University Hospital researcher Joan Sabater, in collaboration with the start-up LoopDx, developed SeptiLoop, a rapid sepsis diagnostic kit. The result of this project was patented and licensed to the company itself.
Yesterday the award ceremony of the “la Caixa” Foundation scholarships was held. Dr. Albert Antolín, principal investigator of IDIBELL and ICO, received a Junior Leader grant to develop new strategies based on Big Data and artificial intelligence for the design of drugs against cancer that prevent drug resistance.
The play Abans que arribi l’alemany, about Alzheimer’s, and a flash talks session about Parkinson’s, bring neurodegenerative diseases closer to the public.
The Flow Cytometry Platform of the IDIBELL Scientific-Technical Services incorporated new high-performance equipment. It is the Beckman Coulter CytoFLEX SRT Benchtop Cell Separator. The arrival of this state-of-the-art equipment covers the need to renew the cell separation service and makes new and current technological improvements available to researchers. CytoFLEX SRT can meet the requirements for …
Presentation of the new cell sorter of the flow cytometry platform Read More »
The androgen receptor is the main target in the fight against prostate cancer. The study, published in the journal Science Advances, states that the analyzed mutations affect several functional regions of the union domain of the androgen receptor to testosterone.
Yesterday, this association from Sant Joan Despí organized an event in which Dr. Sonia Pernas from IDIBELL and the ICO presented the current situation of breast cancer research.
